NasdaqGM:EYPTPharmaceuticals
EyePoint Pharmaceuticals (EYPT) Valuation Check After DURAVYU Phase 3 And NDA Progress
EyePoint (EYPT) is back in focus after a recent corporate update on DURAVYU, outlining progress in Phase 3 trials for wet age related macular degeneration and diabetic macular edema, along with preparations for a potential NDA filing.
See our latest analysis for EyePoint.
Despite the recent DURAVYU update and funding progress, EyePoint’s share price has been volatile, with a 1 day share price return of a 5.0% decline and a 7 day share price return of a 7.2% decline. However, the 90 day share...